Replies to post #182788 on Innovation Pharmaceuticals Inc (IPIX)

[Ringrock]

Great post Bio!

[Amatuer17]

BH - normally I read all your posts and learn new as they are realistic

With current mc at 122 million - no product in P3 - cash on hand less than 7 million - one product K pure speculation at this time

You are talking about 100x+ appreciation - 12 Billion + and also speculate to make it a 50 B company

Looks unrealistic by normal stretch of imagination.

[mdphd2008]

Spot on biohedge.

I have been following CTIX for over 5 years and consider myself lucky to have come across it. I have both an extensive active clinical medicine as well as research background. Moreover, I have been following the biotech sector for over 20 years.

I have never come across such an exciting opportunity in terms of risk/reward potential as we have with CTIX. The majority of risk is mostly behind us and we are on the brink of finding the true value that may lie ahead.

I am excited for both investors as well as the clinical potential it will offer a wide spectrum of patients across many indications.

[BioTechMaven]

Gotta say I'm in complete agreement with valuations and strategic scenarios.

[slcimmuno]

Shoot for the stars and hit the moon...
All good! I def like the idea of not selling it all too soon, instead testing B and K across multiple areas / indications. With a shot in the Arm, first partnership, and more coin in the piggy bank, I say "let it run, baby, run."

[faraifarai]

Yep--I was simply taking what I view is the lowest/worst case sell per indication category to demonstrate how easy it is to get into the many billions with where the pipeline currently is. Crazy to think about how limitless the potential seems with Brilacidin. It seems to work all over the skin, in every hole it enters (pardon the crudeness) and without any/nasty side effects. If i had any of these ailments, i'd be asking for the B straight away. I think FDA Breakthrough designation for oral mucositis is not a matter of if but when. No preventative exists and their interim data is absurdly good. FDA probably waiting for more patients for statistical relevance, and guessing that number is probably double the interim...so july for breakthrough? that's a catalyst that could add a fast $100-$200M in market cap.

[joseytheoutlawwales]

These numbers are compelling to say the least.
Hard to imagine when the PPS cannot seem to find support at even $1.

But we all know the science and solid data could trump all.